NASDAQ$OMER

Omeros Corp · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Omeros reported a net loss for Q1 2021, but saw increased OMIDRIA revenues.

Omeros Corporation reported first quarter 2021 financial results, with OMIDRIA revenues at $21.1 million. The company's net loss was $35.1 million, or $0.57 per share. As of March 31, 2021, Omeros had $100.5 million in cash, cash equivalents and short-term investments.

  • OMIDRIA revenues for Q1 2021 were $21.1 million.
  • Net loss in Q1 2021 was $35.1 million, or $0.57 per share.
  • Omeros had cash, cash equivalents and short-term investments of $100.5 million as of March 31, 2021.
  • Dosing of patients with narsoplimab in the I-SPY COVID-19 platform trial began in March 2021.

Headline financials

Total Revenue

$21.1M

Previous: $23.5M-10.5%
EPS (adj)

-$0.57

Previous: -$0.53-7.5%
Capital Expenditures

-$12K

Previous: -$66K+81.8%
Free Cash Flow

-$35.1M

Previous: -$29.1M-20.6%
Net Income

-$35.1M

Previous: -$29M-20.9%
Operating Income

-$30.6M

Previous: -$23.7M-29.3%
Gross Profit

$20.8M

Previous: $23.3M-10.6%
Cash & Equivalents

$9.03M

Previous: $7.12M+26.8%
Total Assets

$161M

Previous: $118M+36.6%
Stock-Based Comp

$3.27M

No prior period

Revenue & EPS history

Omeros · Revenue · Quarterly

$21.1M

Q1 2021-10.5%vs Q1 2020
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Omeros · $31.9M total across 1 segment · Q4 2021

  • OMIDRIA royalties
    $31.9M

Forward guidance

Omeros is progressing toward the anticipated launch of narsoplimab for TA-TMA and building momentum with OMIDRIA following CMS' confirmation of separate payment for OMIDRIA in the ASC setting.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+2.4%

Avg return

Earnings day

+4.6%

Avg return

5 days after

+7.1%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+64.2%

Q4 2019

Best reaction

-21.2%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+7.5%-7.1%
Q1 2026-2.5%-20.8%-40.9%
Q3 2025+26.3%+30.9%+61.6%
Q2 2025+7.0%+1.7%+0.7%
Q1 2025-18.7%-21.3%-13.9%
Q4 2024-3.8%-14.1%-14.6%
Q3 2024+63.1%+39.0%+79.1%
Q2 2024-10.5%-2.1%-16.7%
Q1 2024-21.2%-21.4%-3.3%
Q4 2023-11.6%-0.6%-1.4%
Q3 2023-3.8%+14.6%+97.7%
Q2 2023-1.2%-6.1%-20.7%
Q1 2023+21.2%+14.2%+51.4%
Q4 2022+15.6%+8.6%+72.1%
Q3 2022-16.9%-10.9%-35.6%
Q2 2022+10.5%+5.6%-19.4%
Q1 2022-5.4%+15.9%-22.5%
Q4 2021-5.1%-11.2%-16.5%
Q3 2021+7.6%+10.1%+6.3%
Q2 2021+1.5%+4.4%+5.3%
Q1 2021+3.8%+2.5%-9.6%
Q4 2020+1.2%-7.3%-10.7%
Q3 2020+6.1%+11.3%+37.0%
Q2 2020+12.5%-4.0%-22.2%
Q1 2020-6.2%-12.0%-2.2%
Q4 2019+64.2%+51.8%+8.7%
Q3 2019+2.2%-3.9%-3.9%
Q2 2019+14.7%+20.6%+14.4%
Q1 2019+5.1%+0.9%-8.3%
Q4 2018+12.5%+9.2%+20.5%
Q3 2018-20.3%-22.2%-14.2%
Q2 2018-18.0%-4.7%+16.9%
Q1 2018+18.0%+45.0%+8.7%
Q4 2017-0.9%-0.1%+10.6%
Q3 2017+27.5%+33.1%+37.5%
Q2 2017+12.4%+5.9%-6.8%
Q1 2017-7.7%-6.4%-4.7%
Q4 2016-7.9%-2.9%+34.7%
Q3 2016+28.7%+45.8%+9.4%
Q2 2016+3.0%-7.9%-8.9%
Q1 2016-15.0%
Q4 2015+24.7%
Q3 2015-1.3%
Q2 2015-3.1%
Q1 2015+4.8%
Q4 2014-6.2%
Q3 2014+9.7%
Q2 2014-5.7%
Q1 2014-6.9%
Q4 2013-11.7%
Q3 2013-5.6%
Q2 2013-7.2%
Q1 2013+17.5%
Q4 2012-3.7%
Q3 2012-17.1%
Q2 2012-2.2%
Q1 2012-0.6%
Q4 2011-3.5%
Q3 2011-2.0%
Q2 2011+3.0%
Q1 2011-0.8%
Q4 2010-3.8%
Q3 2010-3.2%
Q2 2010-12.3%
Q1 2010-3.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro